Idiopathic Thrombocytopenic Purpura (ITP) Clinical Trials

A listing of Idiopathic Thrombocytopenic Purpura (ITP) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 52 clinical trials
Eltrombopag Plus Diacerein vs Eltrombopag in Adult ITP

Primary immune thrombocytopenia (ITP) is an autoimmune bleeding disorder with low platelet count. As the first choice of the second-line treatment of ITP, thrombopoietin receptor agonist (TPO-RA

eltrombopag
platelet count
  • 0 views
  • 19 Jun, 2021
  • 1 location
Dexamethasone Compared to Non-steroidal Anti-inflammatory Drugs in the Treatment of Acute Pericarditis

of action, relatively long duration of action and is therefore often given in high doses for short periods. Dexamethasone has been shown to be a safe therapeutic option in ITP (Immune

  • 0 views
  • 19 Mar, 2021
  • 1 location
A Study of PRN1008 in Adult Patients With Immune Thrombocytopenia (ITP)

This is a 2 part (Part A and B) adaptive, open-label, dose-finding study of PRN1008 in patients with ITP who are refractory or relapsed with no available and approved therapeutic options, with a platelet count <30,000/L on two counts no sooner than 7 days apart in the 15 days before …

thrombocytopenia
platelet count
autoimmune thrombocytopenia
  • 450 views
  • 23 Jul, 2021
  • 64 locations
Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients

and immune thrombocytopenic purpura (ITP) patients. The pharmacodynamics of the drug will be measured as platelet response in patients with ITP.

igiv
immune globulin
  • 489 views
  • 02 Apr, 2021
  • 30 locations
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

This is a randomized, double-blind study of rilzabrutinib in patients with persistent or chronic ITP, with an average platelet count of <30,000/L on two counts at least 5 days apart in the 14 days before treatment begins. Patients will receive rilzabrutinib or placebo 400mg twice daily.

thrombocytopenia
platelet count
  • 0 views
  • 24 Jul, 2021
  • 51 locations
A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)

Primary Objective: To evaluate the effect of BIVV020 on the durability of platelet response in participants with persistent/chronic immune thrombocytopenia (ITP)

splenectomy
fostamatinib
thrombocytopenia
igiv
thrombopoietin receptor agonists
  • 0 views
  • 09 Jun, 2021
  • 9 locations
Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for 6 Months

A Phase 3b Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects with Immune Thrombocytopenia for 6 Months

thrombocytopenia
avatrombopag
  • 0 views
  • 26 Jun, 2021
  • 37 locations
A First in HumanTrial to Evaluate The Safety Tolerability And Pharmacokinetics Of PF-06755347

This phase 1 single ascending dose study will provide a first in human assessment of safety and tolerability of PF-06755347 in healthy adult male subjects. The pharmacokinetics and pharmacodynamics will also be evaluated.

administered intravenously
heart failure
malignancy
cancer
  • 167 views
  • 27 Apr, 2021
  • 5 locations
Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes

thrombocytopenia, in the presence of bleeding, is platelet transfusion. Eltrombopag is an orally bioavailable agonist of the thrombopoietin receptor. In adult patients with chronic immune thrombocytopenia

azacitidine
g-csf
cell transplantation
neutropenia
blood transfusion
  • 19 views
  • 23 Jan, 2021
  • 82 locations
Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

This is an investigator initiated, multicenter, open label, randomized phase 3 study for subjects with newly diagnosed ITP from ages 1 to less than 18 years old.

igiv
thrombocytopenia
immunoglobulins
platelet count
autoimmune thrombocytopenia
  • 10 views
  • 26 Jan, 2021
  • 11 locations